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Elevated plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2)
activity have been shown to be associated with increased risk of coronary
heart disease and an inhibitor of this enzyme is under development for the
treatment of that condition. A Val279Phe null allele in this gene, that may
influence patient eligibility for treatment, is relatively common in East Asians
but has not been observed in Europeans. We investigated the existence and
functional effects of low frequency alleles in a Western European population
by re-sequencing the exons of PLA2G7 in 2000 samples. In all, 19 non-
synonymous single-nucleotide polymorphisms (nsSNPs) were found, 14 in
fewer than four subjects (minor allele frequency o0.1%). Lp-PLA2 activity
was significantly lower in rare nsSNP carriers compared with non-carriers
(167.8±63.2 vs 204.6±41.8, P¼0.01) and seven variants had enzyme
activities consistent with a null allele. The cumulative frequency of these
null alleles was 0.25%, so o1 in 10 000 Europeans would be expected to
be homozygous, and thus not potentially benefit from treatment with an
Lp-PLA2 inhibitor.
The Pharmacogenomics Journal (2012) 12, 425–431; doi:10.1038/tpj.2011.20;
published online 24 May 2011
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Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2), encoded by PLA2G7, is
abundant in coronary atherosclerotic plaque and generates pro-inflammatory
mediators from oxidized low-density lipoprotein particles. Elevated levels of the
enzyme activity have been associated with an increased risk of coronary heart
disease in large epidemiological studies.1 These observations have prompted
the development of inhibitors (darapladib) to this enzyme as a treatment for
coronary heart disease.2
One variant within PLA2G7, Val279Phe, ranges in allele frequency from 4 to
18% in East Asian populations and abolishes enzyme activity,3 so that 279Val/
279Phe heterozygotes have roughly 50% of the activity of homozygous 279Val
carriers, and homozygous carriers of the minor allele have almost no measurable
activity. This variant has been only rarely observed within Europeans, though
other common variants with very small effects on enzyme activity have been
identified in various ethnic groups.4 Here, we hypothesized that rare coding
variants with large effects on enzyme activity would exist in Europeans, as is the
case for other traits, such as triglycerides5 and blood pressure6 and that these
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variants may account for a certain proportion of the inter-
individual variability in plasma Lp-PLA2 levels.
To test this hypothesis, we re-sequenced the PLA2G7
coding regions of 2000 individuals from the CoLaus
population-based study in Lausanne, Switzerland7 to identi-
fy coding single-nucleotide polymorphisms (SNPs) and
more specifically non-synonymous SNPs (nsSNPs). We then
predicted the effect of these nsSNPs on protein function by
means of Sorting Intolerant from Tolerant (SIFT8,9) and
Polymorphism Phenotyping (PolyPhen10,11) algorithms and
estimated their effect on enzyme activity. We also performed
a qualitative structural assessment based on the available
crystal structure of Lp-PLA2 enzyme, to assess the degree of
corroboration with both the SIFT and PolyPhen algorithms.
Subsequently, we examined the association between nsSNPs
in PLA2G7 and a variety of cardiovascular, metabolic and
psychiatric traits to determine the phenotypic consequences
of carriage of likely loss-of-function alleles.
Materials and methods
Study sample
CoLaus is a population-based study of 6188 Lausanne
residents aged 35–75 years.7 In brief, the study assessed
cardiovascular disease risk factors and collected DNA,
plasma, serum and urine samples. For the current study,
we limited our evaluation to 2000 unrelated CoLaus subjects
aged 35–66 years who had also undergone a psychiatric
evaluation (PsyCoLaus12). The project was approved by the
Local Ethics Committee and each participant consented for
the use of their data and samples for this study.
DNA sequencing
Assay design for directed sequencing was performed at
Beckman Coulter Genomics (Danvers, MA, USA) using the
Beckman Coulter Genomic amplicon design software based
on NCBI RefSeq build 36.3. PCR was performed using
validated primer sets and standard conditions. Sequencing
was performed on both strands using the M13 forward and
reverse priming sites in a 384-well format. Sequencing
reagents were subjected to thermal cycling at 95 1C for
10 s, 50 1C for 5 s and 60 1C for 2 12 min for 40 cycles. The PCR
products were loaded on ABI 3730xl automated sequencing
instruments (Foster City, CA, USA). Amplicons that passed
quality review were analyzed to identify single base
differences relative to the reference sequence using Poly-
Phred v.5.04 and v.6.0.13,14 Genotype calls for all subjects at
each coding variant position were manually reviewed.
Enzyme activity measurement
Lp-PLA2 activity was measured on 300 ml of EDTA-sourced
plasma samples using a colorimetric activity method at
Quest Diagnostics (Nicholls Institute). Plasma samples were
reacted with 1-myristoyl-2-(4-nitrophenylsuccinyl) phos-
phatidylcholine in a 96-well microtiter plate. The change
in the absorption at 405 nm in kinetic mode, which is
proportional to the activity of Lp-PLA2 in the sample, was
measured. The serum samples had been stored for
3.4–6.4 years.
Statistical analyses
Association between plasma Lp-PLA2 activity and prediction
score by SIFT or PolyPhen was assessed using a robust linear
regression model adjusting for storage duration of serum,
carrier status and gender. Multiple logistic and linear
regression was performed with selected covariates to test
the association between common variants (defined here as
minor allele frequency (MAF)40.5%) and clinical pheno-
types. Rare variants (MAFo0.5%), were analyzed by aggre-
gating across variants.15 Two analyses were done, the first
aggregating all non-synonymous rare variants and the
second including only those predicted to be deleterious by
PolyPhen and SIFT. Covariates included age, gender, smok-
ing status, alcohol usage, physical activity and the first five
principle components, computed from previously reported
genome-wide genotype data16,17 using EIGENSOFT version
2.0.18 All statistical analyses were carried out using SAS v9.2
(Cary, NC, USA). A 5% significance threshold was deter-
mined by adjusting for the number of analyzed traits using
Bonferroni’s correction. We estimated the proportion of
variance in Lp-PLA2 activity explained by rare variants using
standard quantitative genetic formulae19 by considering
aggregated rare variants as a single locus, assuming an
additive model and using observed genotypic values and
MAF. The genotypic values for this calculation were
estimated by multivariate regression adjusted for storage
duration of serum, high-density lipoprotein cholesterol and
low-density lipoprotein cholesterol.
Results
We re-sequenced all coding (1325 bp) and non-coding
(4909 bp) exons, as well as flanking intronic sequence
(513 bp), of PLA2G7 in 2000 unrelated CoLaus subjects. A
total of 128 variants were identified (see Supplementary
Figure 1), including 26 coding variants of which 19 resulted
in amino-acid changes (Table 1). Most non-synonymous
variants (16; 84%) were rare (MAF o0.5%), of which 10
(53%) were observed in just one heterozygous individual,
that is, singleton variants. One individual was heterozygous
for two rare nsSNPs, Arg82His (MAF¼0.08%) and As-
p181Gly (singleton) of unknown phase. We observed one
carrier of the Val279Phe null allele commonly found in East
Asians. Principal component analysis using previously
generated genome-wide association study data showed that
this individual clusters with other CoLaus subjects having
Swiss rather than Asian ancestry (see Supplementary
Figure 2), demonstrating that this allele is present at very
low frequency in Europeans.
SIFT and PolyPhen protein function predictions were
highly concordant. Both algorithms predicted the three
common variants (Arg92His, Ile198Thr and Val379Ala) to
be benign. Of the rare variants, 12 were predicted to be
damaging and 3 benign (Table 1). Only one variant
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(Asp200His) was predicted to be damaging by SIFT but
benign by PolyPhen.
A qualitative assessment of the expected impact of these
amino-acid changes was also performed based on analysis of
an Lp-PLA2 crystal structure (Table 1). As shown in Figure 1,
the SNPs are widely distributed throughout the three-
dimensional structure. In cases where an SNP occupies a
position within a particular secondary structural element
and is buried within the core of the protein without any
apparent room for that particular residue substitution, it was
predicted that there could be an impact on protein stability
and possibly function. Likewise, if the SNP lies within or
near the active site and appears likely to directly, or
indirectly affect protein function (for example, via substrate
binding or turnover), then such a prediction was also made,
with mutation of the catalytic serine being an obvious
example. In contrast, residues with side chains that are
highly solvent exposed and far from the active site were
predicted to not have an effect on function. Some cases
appeared borderline and were classified as such. Results were
found to be generally concordant with the SIFT and
PolyPhen predictions, and in agreement with a smaller scale
assessment of the impact of polymorphisms by Samanta and
Bahnson.20 There was one exception though, in that
Lys191Asn was predicted to have a negative impact on
function by SIFT and PolyPhen, but not by the structural
assessment. The basis of the structural prediction was that
Lys191 is part of a solvent-exposed loop and is roughly 30 A˚
from the catalytic serine. However, it cannot be ruled out
that phenotypic effects due to this SNP might be due to
modulation of lipoprotein binding interactions, as pointed
out by Samanta and Bahnson for another nearby solvent-
exposed SNP (Ile198Thr).
To determine the effect of these nsSNPs on Lp-PLA2
enzyme activity, we selected all 29 rare nsSNP carriers with a
serum sample available for analysis. Variant carriers were
matched for age (within 1 year), sex and low-density
lipoprotein cholesterol (within 1 mmol l1) with non-car-
riers in a 1:2 ratio. Characteristics of the subjects selected for
enzyme activity analysis are summarized in Table 2. Only
mean of storage duration of serum sample showed a
statistically significant difference (P¼0.01), with carrier
samples having been stored for a 0.4-year shorter period.
To account for the influence of serum storage duration assay
results, it was included as a covariate in all subsequent
analyses of enzyme activity.
The mean Lp-PLA2 enzyme activity was significantly
lower in carriers than in non-carriers (Table 2). Individual
carrier enzyme activities, adjusted for storage duration of
serum and sex, are shown in Figure 2, expressed as standard
deviations from the mean of non-carriers. The individual
who carried the Val279Phe mutation was a white male,
French-speaking resident of Lausanne reported to have all
four grandparents born in Switzerland and demonstrated a
genetic background similar to other French-speaking Lau-
sanne residents (see Supplementary Figure 2).21 He had an
enzyme activity that was 38% of the mean of non-carriers
(2.8 s.d. below), consistent with previous studies of the
Table 1 Non-synonymous variants observed in PLA2G7 and predicted functional effects
Amino acid MAF a SIFT PolyPhen Structure-based assessment of impact on protein function
Phe51Ile 0.0015 Tolerant Benign No
Asp69Gly 0.00025 Deleterious Probably damaging Yes
Arg82His 0.00076 Deleterious Probably damaging Yes
Arg92His 0.25 Tolerant Benign No
Phe110Leu 0.00025 Deleterious Probably damaging Maybe
Trp134***b 0.00031 Deleterious Probably damaging Yes
Asp181Gly 0.00026 Deleterious Probably damaging Yes
Thr187Pro 0.00025 Deleterious Probably damaging Yes
Lys191Asnc 0.00025 Deleterious Probably damaging No
Ile198Thr 0.052 Tolerant Benign No
Asp200Hisc 0.00025 Deleterious Benign No
Ser273Phe 0.00025 Deleterious Probably damaging Yes
Val279Phed 0.00025 Deleterious Probably damaging Yes
Leu283Pro 0.00050 Deleterious Probably damaging Yes
Gly303Cys 0.0018 Deleterious Possibly damaging Maybe
Ala326Val 0.00025 Tolerant Benign No
Met331Lys 0.00025 Deleterious Probably damaging Yes
Val379Ala 0.23 Tolerant Benign No
Glu414Asp 0.00035 Tolerant Benign No
Abbreviations: MAF, minor allele frequency; PolyPhen, Polymorphism Phenotyping; SIFT, Sorting Intolerant from Tolerant.
Bold type indicates the novel non-synonymous variants found in this study.
aMAF in 2000 Europeans.
b***: stop.
cDisagreements among prediction methods.
dAsian null variant known from the literature.
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Val279Phe variant. One subject with a non-sense muta-
tion at position Trp134, which would certainly result in a
non-functional protein, was 1.5 s.d. below the mean,
consistent with the range of Lp-PLA2 activity expected for
carriers of a single functional gene copy. The individual with
lowest enzyme activity was the subject carrying both
Arg82His and Asp181Gly. The measured activity for this
subject was 21.1 nmol ml1 per min, 10% of the mean
of non-carriers, a level approaching values typically obser-
ved in homozygous non-functional Val279Phe variant
carriers,3,22 suggesting that this subject is a compound
heterozygote. This individual was a 39-year-old England-
born man who is healthy with unremarkable phenotype and
no evident disease. Seven carriers with the Gly303Cys
variant had average activity of 173.2 nmol ml1 per min,
84% of the mean of non-carriers, though this reduction was
not statistically significant (P¼ 0.20). Altogether, there were
seven variants carried by nine subjects with a cumulative
frequency of 0.25% with effects similar to those expected for
a null variant with enzyme activity 41 s.d. below the mean
of non-carriers. The six Phe51Ile carriers, an allele predicted
to be benign, had an average activity of 241.7 nmol ml1 per
min, 0.9 s.d. above the mean (P¼ 0.02), suggesting that
this variant may cause an increase in enzyme function.
One other singleton variant, Phe110Leu, had a similarly
increased activity. There was significant association between
Lp-PLA2 enzyme activity and functional predictions ob-
tained by both PolyPhen (Po0.0001; Figures 2 and 3) and
SIFT (P¼0.0001, data not shown). It can further be observed
in Figure 1, that the residues of the likely null variants based
on activity measurements are found in the core of the
protein, close to the active site. Conversely, the non-null
variants are predominantly on the surface of the protein.
We further investigated the effects of both common and
rare nsSNPs in PLA2G7 on other cardiovascular, metabolic
and psychiatric traits. None of the three common variants—
predicted to be benign—were significantly associated with
any trait. Aggregate analysis of rare nsSNPs (cumulative
frequency¼0.8%) also resulted in no statistically significant
associations after Bonferroni’s correction (see Supplemen-
tary Figure 3). Similar association tests were performed for
the 13 predicted functional variants and for the 7 variants
that lead to lower enzyme activity. Neither approach
resulted in statistically significant associations (see Supple-
mentary Figure 3).
Discussion
Complete re-sequencing of the PLA2G7 coding regions in
2000 Europeans identified seven rare non-synonymous
changes in nine carriers, including one compound hetero-
zygote, that lead to a substantial reduction in enzyme
activity. The null allele found at MAFs up to 18% in East
Asians (Val279Phe) was found in one European individual
yielding a MAF estimate of 0.03% (95% confidence interval
0–0.07). This study yields an estimate of the cumulative
frequency of null alleles in the European population to be
0.25% (95% confidence interval 0.09–0.41). Although the
rare loss-of-function variants have relatively large effects on
enzyme activity, their rarity means that they can explain
only a small proportion (B3%) of the European variation.
This compares with an estimate of o1% for Val379Ala,
which although common in Europeans, has a very small
effect on enzyme activity.23
Figure 1 Crystal structure of human lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) showing (a) single-nucleotide polymorphisms
(SNPs) rendered as space-filling spheres, along with a semitransparent
molecular surface indicating the solvent exposure in a qualitative
manner and (b) a cartoon representing the protein backbone,
indicating where SNPs lie along different secondary structural elements.
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SIFT and PolyPhen were predominantly in agreement with
respect to predicted impact on the protein structure and
were also generally concordant with a qualitative structural
assessment utilizing the crystal structure of Lp-PLA2. The
one prediction that differed between the automated and the
qualitative structural approach was that of the Lys191Asn.
Both SIFT and PolyPhen predicted this to be functional, but
the structural assessment did not. Lp-PLA2 activity levels
showed that this variant had no impact on enzyme activity,
though an impact on enzyme–lipoprotein interactions
cannot be ruled out. Overall, in this instance, the structural
predictions worked relatively well in predicting the impact
on enzyme activity.
None of the common variants were associated with the
cardiovascular traits tested. These results are in agreement
with a recent meta-analysis by Casas et al.,4 where they
evaluated these common coding SNPs in 26 118 subjects and
found only Ala379Val to be associated with a very modest
increase in Lp-PLA2 activity (VV 7.2% higher than AA) and
no association with cardiovascular-related traits, angio-
graphic coronary disease or with coronary heart disease
events. Aggregate analysis of the rare nsSNPs also failed to
identify any statistically significant associations with any of
the cardiovascular-related traits examined. Psychiatric traits
were also not associated in either the common variant or
rare aggregated analysis. However, it is difficult to conclude
that no such associations exist, as these analyses have low
power given the limited number of carriers and the modest
relationships between Lp-PLA2 activity and such cardiovas-
cular traits found in other studies.1 Anecdotally, the single
compound heterozygous individual observed in this
study had an unremarkable clinical background, though
was only 39 years old at time of entry into the study. These
data would suggest that natural complete or partial
deficiency in Lp-PLA2 is not clearly detrimental to human
health. However, a much large study would be required to
confirm this.
We attempted to genotype the nsSNPs identified via
sequencing in the remaining 4188 CoLaus samples;
however, most of the rare variants could not be accurately
Table 2 Characteristics of carriers of PLA2G7 rare non-synonymous variants and matched non-carriers
Carriers (N¼29)a Non-carriers (N¼58) P-value
Female 13 (45%) 26 (45%) * b
Age (years) 50.1±8.2 50.1±8.2 *
Body mass index (kgm2) 25.9±4.2 25.3±4.1 0.53
LDL cholesterol (mmol l1) 3.6±0.95 3.5±0.80 0.54
HDL cholesterol (mmol l1) 1.5±0.37 1.6±0.42 0.07
Previous or current alcohol use 21 (72%) 45 (76%) 0.60
Current smoking 9 (31%) 13 (22%) 0.44
Storage duration of serum (years) 4.6±0.67 5.0±0.80 0.04
Lp-PLA2 activity (nmolml1 per min) 167.8±63.2 204.6±41.8 0.01c
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2.
aMean and standard deviation for quantitative variables or count and percent for categorical variables.
bCriteria used for matching.
cModel adjusted for storage duration of serum.
Figure 2 Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in
carriers of rare non-synonymous variants. Enzyme activity is expressed as
standardized residuals (variance of one) adjusting for storage duration of
serum and sex. Circles correspond to carriers of variants predicted to be
functional by Sorting Intolerant from Tolerant (SIFT) or Polymorphism
Phenotyping (PolyPhen) and triangles otherwise. Gray background
indicates the Asian null variant known from the literature.
Figure 3 Relationship between Polymorphism Phenotyping (Poly-
Phen) functional prediction and lipoprotein-associated phospholipase
A2 (Lp-PLA2) activity adjusted for storage duration of serum and sex.
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genotyped (determined based on the comparison with
the sequence-based genotypes in the overlapping portion).
Given the limitations of current genotype calling algorithms
for rare variants and the preponderance of singletons (most
of which would not likely be observed again within another
4000 unrelated subjects), it was clear that sequencing would
be required to investigate this further. This potentially has
broad implications for following up deep re-sequencing
studies. Many of the most functionally relevant variants
will not be amenable to array-based or other standard
forms of large-scale genotyping. They will also fall below
the frequencies that would allow them to be imputed.
If the frequency range of functional variants in PLA2G7
proves to be the norm, then extensive high depth sequen-
cing will be required for the investigation of rare variants
in other genes.
We observed that there is relatively limited value in
investigating the impact of Lp-PLA2-altering variations on
disease risk or related traits in populations of European
ancestry. Instead, it would be much more productive to
focus on studies in East Asian populations where the
functionally validated null Val279Phe variant is much more
common than the cumulative rare variants in Europeans.
We note the similarity to PCSK9 and the demonstration of
its influence on low-density lipoprotein cholesterol and
cardiovascular disease via the functional Y142X and C679X
variants present at a combined frequency of 2% in African
Americans compared with o0.1% in Europeans.24–26 Cur-
rent population-based and case collections are mainly of
European ancestry. Such findings support the development
of similar resources in a wide range of populations, as is
being attempted by the 1000 Genomes Project.27 Finally,
given the very low frequency of functional variants in
PLA2G7, compound heterozygotes or homozygotes in the
phase III trials for darapladib will be extremely rare in
Caucasian populations, B1 in 125 000. These individuals
who will be unlikely to benefit from darapladib can be
detected based on very low enzyme activities, and verified
by sequencing.
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Note added in proof
After this work was accepted, a related paper that describes the
protective effect of the PLA2G7 Asian null variant V279F on
coronary artery disease in Korean males was accepted for
publication (Jang et al, Plos ONE 2011; 6: 1–7).
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